Executive Summary

Validating the preclinical efficacy of LNP-delivered CRISPR-Cas systems requires bioanalytical strategies that move beyond simple quantification of on-target editing. A successful program must demonstrate durable functional protein restoration, characterize the pharmacokinetic and pharmacodynamic relationship, and confirm minimal non-target tissue biodistribution. Franklin Biolabs designs and executes these complex in vivo pharmacology studies, providing the decision-guiding data needed to support an 18-24 month IND timeline.

Defining Efficacy Beyond Allelic Modification

An effective in vivo gene correction program is measured by its ability to produce a lasting therapeutic benefit. While the percentage of edited alleles is a foundational metric, it does not solely define success. The central challenge is to design a pharmacology study that directly links the molecular editing event to a durable, functional outcome in a clinically relevant model.

A robust study plan for an LNP-delivered CRISPR system integrates multiple analytical layers:

• Pharmacokinetic Profiling: Characterizing the systemic exposure and clearance of the LNP construct to inform dose selection and regimen.

• Target Tissue Engagement: Quantifying on-target editing efficiency and resulting protein restoration specifically within the intended organ or cell population.

• Functional Correction: Measuring a definitive reversal of the disease phenotype or normalization of a key physiological biomarker.

• Biodistribution: Performing a comprehensive analysis of non-target tissue biodistribution to understand the specificity of the LNP delivery vehicle.

Benchmarking Durability for Non-Viral Systems

The goal of any gene correction therapy is sustained effect. Seminal studies in the field, including those using viral delivery systems, have established a high bar for durability. For example, research using AAV-mediated delivery to achieve in vivo gene targeting demonstrated stable and long-term therapeutic protein expression, which was maintained even after significant physiological challenge (PMID: 30975639).

While LNP delivery systems operate via a different mechanism: offering a non-viral approach with a distinct immunogenic profile and the possibility of redosing: the therapeutic objective remains the same. Our programs are designed to rigorously assess the durability of LNP-mediated correction, providing the data to determine if the therapeutic effect is stable over time. This is where high-resolution pharmacology validating complex biologicals becomes the central component of a successful IND-enabling package.